Stimcell Energetics (STME) Profit After Tax Growth (1y) (2012 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -18.72% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 13.91% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -12.28% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 99.26% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 4.70% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 125.69% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 89.28% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -27.13% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 51.30% |
| 10 | Stimcell Energetics | - | - | - | 35.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 35.56% |
| Nov 30, 2025 | -122.03% |
| Aug 31, 2025 | -296.90% |
| May 31, 2025 | -75.52% |
| Feb 28, 2025 | -217.14% |
| Nov 30, 2024 | -130.41% |
| Aug 31, 2024 | 13.04% |
| May 31, 2024 | -57.41% |
| Feb 29, 2024 | 201.53% |
| Nov 30, 2023 | 57.60% |
| Aug 31, 2023 | 50.25% |
| May 31, 2023 | 51.17% |
| Feb 28, 2023 | 1.11% |
| Nov 30, 2022 | 18.85% |
| Aug 31, 2022 | 35.37% |
| May 31, 2022 | 13.36% |
| Feb 28, 2022 | 33.25% |
| Nov 30, 2021 | 7.06% |
| Aug 31, 2021 | -18.96% |
| May 31, 2021 | 25.49% |
| Feb 28, 2021 | 30.84% |
| Nov 30, 2020 | 37.61% |
| Aug 31, 2020 | 17.97% |
| May 31, 2020 | 79.07% |
| Feb 29, 2020 | 33.75% |
| Nov 30, 2019 | -138.00% |
| Aug 31, 2019 | -0.75% |
| May 31, 2019 | -409.08% |
| Feb 28, 2019 | -32.07% |
| Nov 30, 2018 | 29.70% |
| Aug 31, 2018 | 70.78% |
| May 31, 2018 | -159.97% |
| Feb 28, 2018 | 2.88% |
| Nov 30, 2017 | 82.89% |
| Aug 31, 2017 | -198.86% |
| May 31, 2017 | 217.95% |
| Feb 28, 2017 | -2.89% |
| May 31, 2013 | 34.58% |
| Feb 28, 2013 | -54.08% |
| Nov 30, 2012 | 18.31% |
| May 31, 2012 | -71.76% |